Cassava Sciences: Phase III trials storm ahead amid controversy

Cassava Sciences: Phase III trials storm ahead amid controversy

Source: 
Clinical Trials Arena
snippet: 

Cassava Sciences is moving forward with Phase III trials after paying $40m to settle an SEC case alleging misleading data from its Phase IIb trial of simufilam.